Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|2|222-228

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.2, 2014-01, pp. : 222-228

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Disease Stabilization in a Patient with Castration-Resistant Metastatic Prostate Cancer by the Addition of Lenalidomide to Low-Dose Dexamethasone and Celecoxib

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 279-282

Karger

Access to resources Recommend Favorite

Chronic Paraneoplastic Cutaneous Syndrome Preceding an Indolent Variant of Mantle Cell Lymphoma: Favorable Response to Rituximab

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 113-116

Karger

Access to resources Recommend Favorite

A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 528-533

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low‐grade B‐cell lymphomas

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 6, 2015-06 ,pp. : 814-823

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low‐dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 277-278

John Wiley & Sons Inc

Access to resources Recommend Favorite